CUFA, ADJ Diabetes Brasil and Merck promote Red Card Day for Diabetes, with blood glucose testing in Heliopolis

To amplify the importance of diabetes awareness month, known as Blue Diabetes November, Central Única das Favelas (CUFA) and ADJ Diabetes Brasil, through the agency InFavela and with the support of Merck Brasil, they will carry out an awareness campaign, with blood glucose testing and professional nutritional and physical activity guidance for residents of the Heliópolis favela, in the city of São Paulo, this Saturday, 11/25. 

"It is estimated that more than 16 million Brazilians currently live with diabetes and that, among them, more than 5 million do not know they have the disease. The problem is that untreated diabetes can lead to serious comorbidities such as the disease kidney disease, glaucoma, arterial problems, amputations, among others. The action with ADJ Diabetes Brasil and CUFA is a way for us to bring information and services to people who have less access to healthcare in Brazil", comments Dr. Ronaldo Wieselberg , doctor endocrinologist and vice-president of ADJ Diabetes Brasil.

During 11/25, Saturday, from 9am to 5pm, Arena Higienópolis will have tents where residents can carry out blood glucose tests, measure weight, height and waist circumference and apply a questionnaire to assess the risk of developing diabetes type 2 in the next 10 years, in addition to the first guidelines with promoters and health professionals from ADJ Diabetes Brasil.

After guidance from ADJ Diabetes Brasil, the public will be directed to the Nutrition and Active Life tents , where they will receive advice on preventing and managing the disease from nutritionists and physical educators, who will give recommendations on balanced eating and physical activity, respectively.

"Diabetes has a significant impact on people's lives, especially in favelas. An awareness event is crucial to disseminate information about the disease and promote health. CUFA, by understanding and identifying the needs of these territories through mapping and identification of problems, seeks to bring understanding and coping with diabetes to the population of these places. This is not just about physical well-being, but also about empowerment and quality of life. The commitment is to provide residents with essential knowledge and resources for a healthy life", explains Kalyne Lima , President of Cufa Brasil.

"Risk factors for developing diabetes include overweight and obesity, family history, physical inactivity and heart disease. In other words, it is important that education about diabetes is promoted to everyone, so that the entire population is aware of their own health.", reinforces Maria Augusta Bernardini , Medical Director for Healthcare at Merck Brasil.  

About diabetes

Diabetes is a chronic disease in which the body does not produce insulin or cannot properly use the insulin it produces. Although it has treatment, it still kills one person every five seconds in the world 1 . Data from the International Diabetes Federation reveal that the number of people with the disease increased by 74 million, totaling 537 million adults worldwide in 2021 1 . In Brazil, the most recent estimates total 15.7 million people with the disease, representing around 7% of the population 1 . 

The risk factors for developing the disease are: overweight and obesity, family history (first-degree relatives with diabetes), physical inactivity, hypertension or heart disease, women who had gestational diabetes and women with PCOS (Polycystic Ovary Syndrome). The risk of developing type 2 diabetes can be reduced by 58% after lifestyle interventions such as a balanced diet, exercise and weight loss 2

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!